AtriCure to Announce First Quarter 2022 Financial Results
April 11 2022 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management, and post-operative pain
management, today announced that it will release its first quarter
2022 financial results on Tuesday, May 3, 2022.
AtriCure will host a conference call at 4:30 p.m. Eastern Time
on Tuesday, May 3, 2022 to discuss its first quarter 2022 financial
results. The call may be accessed through an operator by dialing
(844) 884-9951 for domestic callers and (661) 378-9661 for
international callers, using conference ID number 6061899. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the webcast will be available for 90 days following the
presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220411005100/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Lynn Lewis Gilmartin Group Investor Relations (415) 937-5402
lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024